了解澳大利亚艾滋病毒感染者治疗偏好:一项谨慎选择实验

相关实验视频

Updated: Jul 20, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Simon Fifer¹, Thames Kularatne¹, Marcus Tan²

¹Community and Patient Preference Research Pty Ltd, Sydney, NSW, Australia.

Patient preference and adherence

|August 1, 2023

概括

艾滋病毒感染者 (PLWH) 的治疗偏好各不相同. 成本是最重要的因素,如果成本效益合理,长效注射剂 (LAI) 将占三分之一.

科学领域:

卫生经济学卫生经济学
患者报告的结果
艾滋病毒/艾滋病研究研究

背景情况:

了解患者的偏好对于优化治疗坚持和人类免疫缺陷病毒 (HIV) 管理的结果至关重要.
长效注射 (LAI) 抗逆转录病毒疗法 (ART) 是每日口服药物的替代品,但患者的接受和偏好需要调查.

研究的目的:

确定影响艾滋病毒感染者治疗选择的关键属性 (PLWH).
评估PLWH如何在口服ART和LAI治疗之间权衡风险和益处.
根据治疗偏好,识别不同的患者群体.

主要方法:

与11个PLWH进行了定性深度访谈,以确定决策属性.
一项涉及99名PLWH的离散选择实验 (DCE),将口服ART与假设的LAI治疗进行比较.
隐性类型建模 (LCM) 来分析DCE数据并识别偏好异质性.

主要成果:

在PLWH中观察到治疗偏好的显著异质性.
两个不同的患者群体出现了:一个更喜欢口服ART,另一个更喜欢LAI,特别是如果在GP诊所中进行.
自理成本是影响治疗选择的最重要属性.
大约三分之一的PLWH表示愿意转向LAI治疗.

结论:

在PLWH中治疗偏好不均,并受到各种因素的影响.
出口成本是PLWH治疗选择的主要驱动因素.
建议共享决策,以使治疗计划与个体患者的目标和偏好保持一致.

关键词:

艾滋病病毒艾滋病病毒艾滋病病毒进行联合分析分析.离散选择实验是一个实验.患者的偏好患者的偏好分享决策的决策.治疗目标治疗目标

更多相关视频

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

相关概念视频

Study Designs in Epidemiology

Study Designs in Epidemiology

Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Blinding

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.

Dose-Response Relationship: Selectivity and Specificity

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...